Background: The task of diagnosing growth hormone deficiency (GHD) in adults is cumbersome because of the paucity of biological endpoints. Consequently, over the past decade different organizations have attempted to develop homogeneous criteria and methodology for worldwide use. GHD should be biochemically confirmed within an appropriate clinical context – but only if there is the intention to treat. Clinically, patients investigated for GHD should include those with signs and symptoms or a past history of hypothalamo-pituitary dysfunction and those with a history of cranial irradiation, tumour treatment, traumatic brain injury or subarachnoid haemorrhage. Conclusions: Subjects with ≥3 pituitary hormone deficiencies plus a low insulin-like growth factor I level do not need provocative testing. For those who must be tested, arguably the most commonly used provocative tests are the insulin tolerance test and the glucagon, GH-releasing hormone (GHRH) + arginine and GHRH + GH-releasing hexapeptide tests. Cutoffs differ across tests and results may be influenced by gender, age, body mass index and the assay reference preparation.

Keywords:
Insulin tolerance test, Growth hormone-releasing hormone (GHRH)-arginine, Growth hormone releasing hexapeptide, Glucagon, Insulin-like growth factor I
1.
Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Ingemann-Hansen T, Skakkebek NE, Christiansen JS: Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;1:1221–1225.
2.
Giustina A, Veldhuis JD: Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717–797.
3.
Casanueva FF, Pombo M, Leal A, Popovic V, Dieguez C: Biochemical diagnosis of growth hormone deficiency in adults; in Abs R, Feldt-Rasmussen U (eds): Growth Hormone Deficiency in Adults. 10 Years of KIMS. Oxford, Oxford PharmaGenesis Ltd, 2004, pp 91–101.
4.
Clemmons DR: Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm Res 2001;55(suppl 2):73–79.
5.
Growth Hormone Research Society: Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency. J Clin Endocrinol Metab 1998;83:379–381.
6.
Ho KK, 2007 GH Deficiency Consensus Workshop Participants: Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007;157:695–700.
7.
American Association of Clinical Endocrinologists Growth Hormone Task Force: American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children – 2003 update. Endocr Pract 2003;9:64–76.
8.
Ghigo E, Aimaretti G, Cornelli G: Diagnosis of adult GH deficiency. Growth Horm IGF Res 2008;18:1–16.
9.
Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM: The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab 2003;88:95–102.
10.
Agha A, Rogers B, Sherlock M, O’Kelly P, Tormey W, Phillips J, Thomson CJ: Anterior pituitary dysfunction in survivors of traumatic brain injury. J Clin Endocrinol Metab 2004;89:4926–4936.
11.
Abs R, Mattson AF, Bengtsson BA, Feldt-Rasmussen U, Goth MI, Koltowska M, Monson JP, Verhelst J, Wilton P: Isolated growth hormone deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A subanalysis of the KIMS database. Growth Horm IGF Res 2005;15:349–359.
12.
Tanriverdi F, Unluhizarci K, Kocyigit I, Ibrahim ST, Karaca Z, Durak AC, Selcuklu A, Casanueva FF, Kelestimur F: Brief communication: pituitary volume and function in competing and retired male boxers. Ann Intern Med 2008;148:827–831.
13.
Hoffman DM, Nguyen TV, O’Sullivan AJ, Baxter RC, Ho KK: Diagnosis of growth hormone deficiency in adults. Lancet 1994;344:482–483.
14.
Gomez JM, Espadero RM, Escobar F, Hawkins F, Pico A, Herrera JL, Vilardell E: Duran A, Mesa J, Faure E, Sanmarti A: Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults. Clin Endocrinol 2002;56:329–334.
15.
Aimaretti G, Cornelli G, Razzore P, Bellone J, Baffoni C, Arvat E, Camanni F, Ghigo E: Comparison between insulin-induced hypoglycaemia and growth hormone (GH)-releasing hormone+arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 1998;83:1615–1618.
16.
Popovic V, Leal A, Micic D, Koppeschaar HP, Torres E, Paramo C, Obradovic S, Dieguez C, Casanueva FF: GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH deficient adults. Lancet 2000;356:1137–1142.
17.
Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF: Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995;80:942–947.
18.
Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Harman ML: Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002;87:2067–2079.
19.
Kelestimur F, Popovic V, Leal A, Van Dam Sytze P, Torres E, Perez Mendez LF, Greenmant Y, Koppeschaar HPF, Dieguez C, Casanueva FF: Effect of obesity and morbid obesity on the growth hormone (GH) secretion elicited by the combined GHRH + GHRP-6 test. Clin Endocrinol 2006;64:667–671.
20.
Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ: Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002;87:477–485.
21.
Jansson C, Boguszewski C, Rosberg S, Carlsson L, Albertsson K: Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clin Chem 1997;43:950–956.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.